ENSPRYNG (satralizumab)
Moderate-to-severe thyroid eye disease · Adults with moderate-to-severe active thyroid eye disease
RHHBY · Roche Holdings AG
Regulatory designations
Full timeline
4 milestonesFDA approved ENSPRYNG for thyroid eye disease
FDA approved ENSPRYNG for adults with thyroid eye disease, making it the first FDA-approved at-home subcutaneous treatment option for the condition.
Roche — ENSPRYNG FDA approval announcement↗FDA decision expected
FDA assigned an October 15, 2026 PDUFA goal date to the ENSPRYNG supplemental BLA for thyroid eye disease.
Roche — Enspryng sBLA acceptance and PDUFA date↗FDA accepted the sBLA with Priority Review
FDA accepted the ENSPRYNG supplemental BLA and granted Priority Review for the treatment of thyroid eye disease.
Roche — Enspryng sBLA acceptance and Priority Review↗SatraGO Phase 3 data were presented
Roche presented Phase 3 SatraGO-1 and SatraGO-2 results showing improvements across key thyroid eye disease endpoints, including proptosis and diplopia.
Roche — SatraGO programme data and regulatory update↗Related News
FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
Nov 16, 2026Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
Nov 13, 2026CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)
Nov 10, 2026Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer’s disease portfolio at CTAD 2026
Oct 28, 2026Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma
